Cocrystal Pharma Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 10

Employees

  • Stock Symbol
  • COCP

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.01
  • (As of Tuesday Closing)

Cocrystal Pharma General Information

Description

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Contact Information

Formerly Known As
Biozone Pharmaceuticals, Cocrystal Discovery
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 19805 North Creek Parkway
  • Bothell, WA 98011
  • United States
+1 (678)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 19805 North Creek Parkway
  • Bothell, WA 98011
  • United States
+1 (678)

Cocrystal Pharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cocrystal Pharma Stock Performance

As of 17-Nov-2026, Cocrystal Pharma’s stock price is $1.01. Its current market cap is $19.5M with 19.3M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.01 $0.98 $0.76 - $2.03 $19.5M 19.3M 44.9K -$0.76

Cocrystal Pharma Financials Summary

As of 30-Sep-2026, Cocrystal Pharma has a trailing 12-month revenue of $435K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 21,325 7,349 9,406 (12,099)
Revenue 435 0 0 0
EBITDA (11,060) (8,589) (17,595) (18,624)
Net Income (11,333) (8,831) (17,504) (17,984)
Total Assets 6,773 9,712 13,456 31,259
Total Debt 1,257 1,505 1,806 1,853
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cocrystal Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cocrystal Pharma‘s full profile, request access.

Request a free trial

Cocrystal Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Cocrystal Pharma‘s full profile, request access.

Request a free trial

Cocrystal Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the
Drug Discovery
Bothell, WA
10 As of 2025

Cambridge, MA
 

Abingdon, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cocrystal Pharma Competitors (60)

One of Cocrystal Pharma’s 60 competitors is Marengo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Altimmune Formerly VC-backed Gaithersburg, MD
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 60 competitors. Get the full list »

Cocrystal Pharma Patents

Cocrystal Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4384178-A1 Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza Pending 11-Aug-2021
EP-4384178-A4 Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza Pending 11-Aug-2021
US-20250230161-A1 Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza Pending 11-Aug-2021
WO-2023018913-A1 Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza Inactive 11-Aug-2021
JP-2024530920-A Inhibitors against coronaviruses Pending 03-Aug-2021 A61K31/4015
To view Cocrystal Pharma’s complete patent history, request access »

Cocrystal Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cocrystal Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cocrystal Pharma‘s full profile, request access.

Request a free trial

Cocrystal Pharma Acquisitions (2)

Cocrystal Pharma’s most recent deal was a Merger/Acquisition with RFS Pharma for . The deal was made on 25-Nov-2014.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
RFS Pharma 25-Nov-2014 Merger/Acquisition Drug Discovery
Biozone Pharmaceuticals 02-Jan-2014 Merger/Acquisition Personal Products
To view Cocrystal Pharma’s complete acquisitions history, request access »

Cocrystal Pharma ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Cocrystal Pharma’s complete esg history, request access »

Cocrystal Pharma FAQs

  • When was Cocrystal Pharma founded?

    Cocrystal Pharma was founded in 2008.

  • Where is Cocrystal Pharma headquartered?

    Cocrystal Pharma is headquartered in Bothell, WA.

  • What is the size of Cocrystal Pharma?

    Cocrystal Pharma has 10 total employees.

  • What industry is Cocrystal Pharma in?

    Cocrystal Pharma’s primary industry is Drug Discovery.

  • Is Cocrystal Pharma a private or public company?

    Cocrystal Pharma is a Public company.

  • What is Cocrystal Pharma’s stock symbol?

    The ticker symbol for Cocrystal Pharma is COCP.

  • What is the current stock price of Cocrystal Pharma?

    As of 17-Nov-2026 the stock price of Cocrystal Pharma is $1.01.

  • What is the current market cap of Cocrystal Pharma?

    The current market capitalization of Cocrystal Pharma is $19.5M.

  • What is Cocrystal Pharma’s current revenue?

    The trailing twelve month revenue for Cocrystal Pharma is $435K.

  • Who are Cocrystal Pharma’s competitors?

    Marengo Therapeutics, Adaptimmune Therapeutics, Altimmune, Sorrento Therapeutics, and Immunocore Holdings are some of the 60 competitors of Cocrystal Pharma.

  • What is Cocrystal Pharma’s annual earnings per share (EPS)?

    Cocrystal Pharma’s EPS for 12 months was -$0.76.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process